Valeritas makes V-Go, a disposable device for delivering basal-bolus insulin therapy in adults with Type 2 diabetes. The V-Go provides a continuous preset basal rate of insulin and allows on-demand bolus dosing around mealtimes, offering an alternative to multiple daily injections. Led by CEO Kristine Peterson, the company is based in Bridgewater, N.J. Valeritas closed a $100M structured debt financing with Capital Royalty L.P. The company intends to use the proceeds to further support U.S. commercialization of the V-Go. Valeritas previously raised $150M in equity financing in 2011. Valeritas develops drug-delivery solutions for diabetes, centered on its V-Go disposable insulin delivery device. The V-Go provides basal-bolus insulin therapy for adult patients who require insulin. The company intends to use the financing to support commercialization efforts for V-Go. Valeritas operates R&D and manufacturing in a facility in Shrewsbury, MA and is led by CEO Kristine Peterson. The company announced a $150M Series C financing in December 2011. As part of the transaction, Welsh, Carson, Anderson & Stowe will assume a controlling interest and a WCAS executive will join the board.

Total raised

$250M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Jun 2013